Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Fluphenazine Decanoate
Generic Name
Fluphenazine Decanoate
Active Ingredient
FluphenazineCategory
Other
Salt Form
Hydrochloride
Variants
9
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Fluphenazine Decanoate, you must consult a qualified healthcare professional.
| 63323-272 |
| 25 mg/mL | INJECTION, SOLUTION | INTRAMUSCULAR, SUBCUTANEOUS | 68083-476 |
| 25 mg/mL | INJECTION, SOLUTION | INTRAMUSCULAR, SUBCUTANEOUS | 67457-359 |
| 25 mg/mL | INJECTION, SOLUTION | INTRAMUSCULAR, SUBCUTANEOUS | 42023-129 |
| 25 mg/mL | INJECTION | INTRAMUSCULAR, SUBCUTANEOUS | 0143-9529 |
| 25 mg/mL | INJECTION, SOLUTION | INTRAMUSCULAR, SUBCUTANEOUS | 25021-838 |
Detailed information about Fluphenazine Decanoate
Fluphenazine is a high-potency typical antipsychotic belonging to the phenothiazine class. It is primarily utilized for the management of schizophrenia and other psychotic disorders by modulating dopamine activity in the brain.
Dosage for Fluphenazine must be highly individualized, as the optimal therapeutic dose varies significantly between patients. Healthcare providers typically aim for the lowest effective dose to minimize the risk of neurological side effects.
Fluphenazine is generally not recommended for use in children under the age of 12. For adolescents over 12, healthcare providers may occasionally prescribe low doses if other first-line treatments are ineffective. However, because of the high risk of extrapyramidal side effects (involuntary movements) in younger populations, extreme caution is required. Pediatric dosing, when used, usually begins at the lowest possible range (e.g., 0.25 mg to 0.5 mg daily) and is titrated very slowly under the close supervision of a child psychiatrist.
While Fluphenazine is primarily metabolized by the liver, its metabolites are excreted by the kidneys. In patients with significant renal (kidney) impairment, the clearance of these metabolites may be reduced. Doctors may choose to start at the lower end of the dosing spectrum and monitor kidney function tests (BUN and Creatinine) regularly.
Because the liver is the primary site of Fluphenazine metabolism, patients with hepatic (liver) disease are at a significantly higher risk of drug accumulation and toxicity. Lower initial doses and slower titration are mandatory. If liver enzymes (ALT/AST) become significantly elevated during treatment, the medication may need to be discontinued.
Geriatric patients are particularly sensitive to the effects of Fluphenazine. They are at a much higher risk for orthostatic hypotension (a sudden drop in blood pressure when standing) and tardive dyskinesia. Healthcare providers typically start elderly patients on 1 mg to 2.5 mg daily and increase the dose very gradually.
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take two doses at once to "make up" for a missed one, as this increases the risk of acute side effects.
An overdose of Fluphenazine is a medical emergency. Symptoms may include severe extrapyramidal reactions (muscle rigidity, tremors), extreme sedation, low blood pressure (hypotension), and potentially life-threatening heart rhythm disturbances. If an overdose is suspected, contact a poison control center or emergency services immediately. Treatment is primarily supportive and may involve gastric lavage (stomach pumping) and the administration of intravenous fluids or medications to counteract muscle rigidity.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Abruptly stopping the medication can lead to a return of psychotic symptoms or withdrawal-like effects.
Because Fluphenazine is a high-potency dopamine blocker, side effects related to the nervous system are very common.
Fluphenazine is a powerful medication that requires careful medical supervision. Patients should be aware that this drug can impair the mental and physical abilities required for driving or operating heavy machinery. This effect is most pronounced during the first few days of treatment or following a dose increase. Additionally, Fluphenazine can affect the body's ability to cool itself down, making patients more susceptible to heatstroke during hot weather or vigorous exercise.
Elderly Patients with Dementia-Related Psychosis: Clinical trials have shown that elderly patients with dementia-related psychosis who are treated with antipsychotic medications face a significantly higher risk of death compared to those receiving a placebo. Most deaths were related to heart problems or infections like pneumonia. Fluphenazine is strictly not indicated for the treatment of psychosis associated with dementia.
Certain medications should never be used in combination with Fluphenazine due to the risk of life-threatening complications:
Fluphenazine must NEVER be used in the following circumstances:
Fluphenazine is classified by the FDA as Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, and there are no adequate and well-controlled studies in humans. However, the potential benefits may warrant use of the drug in pregnant women despite potential risks.
There is a risk of Extrapyramidal Signs (EPS) and withdrawal symptoms in newborns whose mothers took Fluphenazine during the third trimester. These symptoms in the neonate may include agitation, hypertonia (increased muscle tone), hypotonia (decreased muscle tone), tremor, somnolence, and respiratory distress. Use during pregnancy should only occur if the clinical need for treating the mother's psychosis outweighs the risk to the fetus.
Fluphenazine is known to be excreted in human breast milk. Because of the potential for serious adverse reactions in nursing infants (such as extreme sedation and movement disorders), a decision should be made whether to discontinue nursing or discontinue the drug. In most cases, if Fluphenazine is essential for the mother's health, healthcare providers recommend alternative feeding methods for the infant.
Fluphenazine exerts its primary therapeutic effect through the potent antagonism of Dopamine D2 receptors in the mesolimbic and mesocortical tracts of the brain. By binding to these receptors, it inhibits the overactive dopaminergic neurotransmission that characterizes the "positive" symptoms of schizophrenia. Unlike atypical antipsychotics, Fluphenazine has a very high binding affinity for the D2 receptor, often referred to as "tight binding," which explains its high potency and its propensity for causing extrapyramidal symptoms. It also possesses minor blocking activity at Alpha-1 adrenergic, H1 histaminergic, and M1 muscarinic receptors.
The onset of action for oral Fluphenazine Hydrochloride is typically within 1 hour, with peak effects occurring between 2 and 4 hours. The duration of effect for a single oral dose is roughly 6 to 8 hours, though the antipsychotic effect builds over several weeks of consistent dosing. Tolerance to the sedative effects often develops within the first two weeks, but tolerance to the antipsychotic effects does not typically occur.
Common questions about Fluphenazine Decanoate
Fluphenazine is primarily used to treat the symptoms of schizophrenia and other psychotic disorders. It is a high-potency antipsychotic that helps manage hallucinations, delusions, and disorganized thinking by balancing dopamine levels in the brain. Healthcare providers may also use it for long-term maintenance therapy to prevent the recurrence of psychotic episodes. While it is highly effective for these conditions, it is generally not used for mild anxiety or non-psychotic behavioral issues. Your doctor will determine if your specific symptoms warrant the use of this potent medication.
The most common side effects of Fluphenazine involve movement-related issues known as extrapyramidal symptoms, such as muscle stiffness, tremors, and a restless need to move (akathisia). Patients also frequently report drowsiness, dry mouth, blurred vision, and constipation, especially when first starting the medication. Some individuals may experience dizziness when standing up due to a drop in blood pressure. Many of these side effects can be managed by adjusting the dose or adding other medications, so it is vital to keep your healthcare provider informed. If you notice any unusual involuntary movements, contact your doctor immediately.
No, you should strictly avoid drinking alcohol while taking Fluphenazine. Alcohol is a central nervous system depressant that can dangerously enhance the sedative effects of the medication, leading to extreme sleepiness and impaired coordination. More seriously, the combination can cause respiratory depression, making it difficult to breathe, and increase the risk of a fatal overdose. Alcohol also interferes with the management of the underlying psychotic condition, potentially making symptoms worse. Always consult your doctor before consuming any substances that can affect your mental clarity while on this treatment.
Fluphenazine is generally not recommended during pregnancy unless the potential benefits significantly outweigh the risks to the fetus. It is classified as FDA Category C, meaning there is evidence of potential harm in animal studies but insufficient data in humans. Infants born to mothers who took Fluphenazine in the third trimester may experience withdrawal symptoms or involuntary muscle movements after birth. If you are pregnant or planning to become pregnant, you must discuss the risks and benefits of continuing this medication with your psychiatrist and obstetrician. They may suggest alternative treatments or monitor the pregnancy and newborn more closely.
While some calming effects or a reduction in agitation may be noticed within the first few days of starting Fluphenazine, the full antipsychotic effect usually takes several weeks. Most patients see a significant improvement in hallucinations and delusions within 2 to 6 weeks of consistent use. It is important to continue taking the medication exactly as prescribed, even if you do not feel better immediately. Stopping the medication too early can prevent it from working effectively and may lead to a relapse of symptoms. Your doctor will monitor your progress and may adjust the dose over the first month to find the most effective level.
You should never stop taking Fluphenazine suddenly without consulting your healthcare provider. Abruptly discontinuing the drug can cause a rapid return of psychotic symptoms, such as hallucinations and severe agitation. It can also lead to withdrawal-like symptoms, including nausea, vomiting, dizziness, and tremors. In some cases, stopping the drug suddenly can trigger temporary movement disorders. If it is necessary to stop the medication, your doctor will provide a gradual tapering schedule to allow your brain and body to adjust slowly and safely.
If you miss a dose of Fluphenazine, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take two doses at once to make up for the one you missed, as this significantly increases the risk of side effects like muscle rigidity or extreme sedation. If you miss multiple doses, contact your healthcare provider for guidance on how to safely restart your medication. Consistency is key to the success of antipsychotic therapy.
Weight gain is a possible side effect of Fluphenazine, though it is generally less common and less severe than with newer 'atypical' antipsychotics like olanzapine. The medication can cause changes in metabolism and increased appetite in some patients. To manage this, healthcare providers recommend monitoring your weight regularly and maintaining a balanced diet and exercise routine. If you notice significant or rapid weight gain, discuss it with your doctor, as they may want to check your blood sugar and cholesterol levels. They can also provide guidance on lifestyle changes to help maintain a healthy weight.
Fluphenazine can interact with many other medications, so it is crucial to provide your doctor with a complete list of everything you are taking, including over-the-counter drugs and herbal supplements. It can have dangerous interactions with other CNS depressants, certain antibiotics, and heart medications. Specifically, it can block the effects of medications used for Parkinson's disease and increase the risk of side effects from anticholinergic drugs. Your doctor will carefully screen for these interactions to ensure that Fluphenazine can be safely integrated into your current treatment regimen. Never start a new medication without checking with your healthcare provider first.
Yes, Fluphenazine is available as a generic medication in several forms, including the hydrochloride tablets and the decanoate injection. Generic versions are typically more cost-effective than brand-name drugs while containing the same active ingredient and meeting the same FDA standards for quality and efficacy. Availability may vary by pharmacy, so it is a good idea to check with your pharmacist regarding the specific generic manufacturer they carry. Using the generic version can make long-term maintenance therapy more affordable for many patients and their families.
Other drugs with the same active ingredient (Fluphenazine)
> Warning: Stop taking Fluphenazine and call your doctor immediately if you experience any of these.
With prolonged use, the risk of developing Tardive Dyskinesia increases significantly. The risk is highest in elderly patients, particularly women. Additionally, long-term use of typical antipsychotics has been associated with "post-psychotic depression" in some individuals. Regular monitoring via the Abnormal Involuntary Movement Scale (AIMS) is recommended every 3 to 6 months for patients on chronic Fluphenazine therapy.
Increased Mortality in Elderly Patients with Dementia-Related Psychosis: The FDA has issued a black box warning for all antipsychotics, including Fluphenazine. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death, primarily due to cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) causes. Fluphenazine is not approved for the treatment of patients with dementia-related psychosis.
Report any unusual symptoms to your healthcare provider. Early detection of side effects is crucial for adjusting the treatment plan safely.
Patients taking Fluphenazine require regular clinical monitoring to ensure safety:
Do not drive, operate heavy machinery, or engage in hazardous activities until you know how Fluphenazine affects you. The sedative effects and potential for blurred vision can significantly impair your reaction time and coordination.
Alcohol must be strictly avoided while taking Fluphenazine. Alcohol increases the central nervous system (CNS) depressant effects of the medication, leading to extreme drowsiness, respiratory depression, and an increased risk of accidental injury or overdose.
Never stop taking Fluphenazine suddenly. Abrupt discontinuation can lead to "withdrawal emergent neurological signs" or a rapid return of psychotic symptoms. If the medication needs to be stopped, your healthcare provider will provide a tapering schedule to slowly reduce the dose over several weeks.
> Important: Discuss all your medical conditions with your healthcare provider before starting Fluphenazine, especially if you have a history of liver disease, kidney disease, seizures, or heart problems.
Fluphenazine can cause false-positive results on certain laboratory tests:
For each major interaction, the mechanism usually involves either a pharmacodynamic interaction (where two drugs have opposing or additive effects on the body) or a pharmacokinetic interaction (where one drug changes how the other is absorbed or metabolized). Management typically involves adjusting dosages, choosing alternative medications, or increasing clinical monitoring.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to prevent dangerous interactions.
In these cases, a healthcare provider must perform a careful risk-benefit analysis:
Patients who have had a severe adverse reaction or allergic response to any phenothiazine antipsychotic are highly likely to have a similar reaction to Fluphenazine. This "cross-sensitivity" occurs because these drugs share a similar chemical structure. Always inform your doctor if you have ever had a bad reaction to any "major tranquilizer" or antipsychotic in the past.
> Important: Your healthcare provider will evaluate your complete medical history, including any past reactions to medications, before prescribing Fluphenazine to ensure it is safe for you.
As previously noted, Fluphenazine is not approved for use in children under 12 years of age. Adolescents may be more susceptible to acute dystonic reactions and other extrapyramidal symptoms. Long-term effects on growth and development have not been extensively studied, making it a second or third-line choice for pediatric psychotic disorders.
Elderly patients require the most caution. They are at the highest risk for:
While the liver does the heavy lifting for metabolism, the kidneys filter the metabolites. In patients with a Glomerular Filtration Rate (GFR) below 30 mL/min, the dose should be reduced by at least 50%, and the patient should be monitored for signs of increased sedation or neurological side effects. Fluphenazine is not significantly cleared by hemodialysis.
For patients with Child-Pugh Class B or C hepatic impairment, Fluphenazine should generally be avoided. If it must be used, the starting dose should be very low (e.g., 0.5 mg to 1 mg), and liver function tests must be monitored weekly during the titration phase.
> Important: Special populations require individualized medical assessment. Always consult with a specialist if you fall into one of these categories.
|---|---|
| Bioavailability | 40% - 50% (due to first-pass metabolism) |
| Protein Binding | 91% - 99% |
| Half-life | 14 - 24 hours (Oral HCl) |
| Tmax | 1.5 - 2 hours |
| Metabolism | Hepatic (Primary: CYP2D6) |
| Excretion | Renal (approx. 50%), Fecal (approx. 50%) |
Fluphenazine is a member of the Phenothiazine class of antipsychotics. Within this class, it is specifically a piperazine phenothiazine. Other medications in this class include perphenazine and trifluoperazine. It is distinct from the butyrophenone class (e.g., haloperidol) and the thioxanthene class (e.g., thiothixene), although all are considered first-generation antipsychotics.